2 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 2, Recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 5 | Unknown 2, Completed 1, Recruiting 1, Terminated 1 |
Follow Advanced Tumors: new trials by email Literature Review of Advanced Tumors trials Research Report on Advanced Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors MDX2004 - Advanced Tumors | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 235 | 2025-10-01 | 2026-03-05 |
| Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms Tarlatamab treatment - DLL3-expressing Tumors, Advanced Tumors | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 29 | 2025-03-21 | 2026-09-01 |
| Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE) Placebo + conventional treatment including radiotherapy, Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine - Advanced Tumors | Phase 2 | Recruiting | The University of Hong Kong-Shenzhen Hospital | 154 | 2024-01-31 | 2025-03-25 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma HLX301 - Advanced Tumors, Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 30 | 2022-06-20 | 2023-08-08 |
| A Study of PM1022 in Patients With Advanced Tumors PM1022 - Advanced Tumors | Phase 1 / Phase 2 | Unknown | Biotheus Inc. | 200 | 2022-04-11 | 2023-05-22 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors HH2710 - Advanced Tumors, Melanoma | Phase 1 / Phase 2 | Terminated | Haihe Biopharma Co., Ltd. | 37 | 2020-01-07 | 2024-07-19 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | Boehringer Ingelheim | 211 | 2019-03-19 | 2026-01-27 |
| Study of BMS-986158 in Subjects With Select Advanced Cancers BMS-986158, Nivolumab - Advanced Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 83 | 2015-06-19 | 2022-06-16 |
Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Erdheim-Chester Disease (1) · Lymphoma (1) · Melanoma (1) · Neoplasms (1)
Neoplasms (3) · Hemic and Lymphatic Diseases (2) · Lymphatic Diseases (2) · Neoplasms by Histologic Type (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Histiocytosis (1) · Histiocytosis, Non-Langerhans-Cell (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lung Diseases (1) · Lung Neoplasms (1)
Nivolumab (1)
Biotheus Inc. (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Haihe Biopharma Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · ModeX Therapeutics, An OPKO Health Company (1) · Shanghai Henlius Biotech (1) · The University of Hong Kong-Shenzhen Hospital (1)
China (4) · United States (4) · Australia (2) · Canada (2) · France (1) · Israel (1) · Spain (1) · United Kingdom (1)
Jonathan Goldman, MD (1) · Ye Guo (1)
2015 (1), 2018 (1)